MIRMMIRMHealthcare · Biotechnology

MIRM Stock Forecast: Mirum Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 17 Nov 2026
$92
+0.40% on the day

The 12 Wall Street analysts covering Mirum Pharmaceuticals, Inc. hold a median 12-month price target of $155 — +68.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 56 of 100 as at 16 Nov 2026 — in the upper half.

Market cap
$6.1B
Ticker Nerd rank
56/ 100
Median analyst target
$155
Analysts covering
12
Revenue$176.2M+37.9% y/y
Operating income−$26.1M
Net income−$67.2M
Free cash flow−$69.3M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−2.6%
1M
+14.7%
YTD
+16.4%
1Y
+27.3%
From 52W high
−28.5%
From 52W low
+43.4%
$64
$129
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

MIRM stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Mirum Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 16 Nov 2026
56/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
92
Value
83
Momentum
78
Accruals
68
Quality
58
Revisions
57
Growth
38
Size
20
Issuance
7

Volatility (92): The share price has been relatively steady.

Issuance (7): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

MIRM stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MIRM, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$50$100$150$200Jan 26Apr 26Jul 26Oct 26MIRMHigh $202Median $155Low $118

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says12 analysts
12 Buy0 Hold0 Sell
Low $118Median $155High $202

The green dot is the last close — the median target sits +68.6% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 11 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
11 Nov 2026CitigroupMaintainsBuy$184 → $194
5 Nov 2026Leerink PartnersMaintainsOutperform$154 → $140
4 Nov 2026Cantor FitzgeraldMaintainsOverweight$155 → $160
4 Nov 2026CitizensMaintainsMarket Outperform$144 → $167
4 Nov 2026HC Wainwright & Co.MaintainsBuy$200 → $202
4 Nov 2026RBC CapitalReiteratesOutperform$155
21 Oct 2026TD CowenMaintainsBuy—
21 Oct 2026TD CowenMaintainsBuy$140 → $145
15 Oct 2026StifelMaintainsBuy$136 → $156
15 Oct 2026StifelMaintainsBuy—
13 Oct 2026Evercore ISI GroupMaintainsOutperform$135 → $146
13 Oct 2026Evercore ISI GroupMaintainsOutperform—
13 Oct 2026Morgan StanleyMaintainsOverweight—
13 Oct 2026Morgan StanleyMaintainsOverweight$137 → $152
12 Oct 2026CitigroupMaintainsBuy—
12 Oct 2026CitigroupMaintainsBuy$160 → $184
12 Oct 2026HC Wainwright & Co.MaintainsBuy—
12 Oct 2026HC Wainwright & Co.MaintainsBuy$195 → $200
8 Oct 2026RBC CapitalMaintainsOutperform—
8 Oct 2026RBC CapitalMaintainsOutperform$135 → $155

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

MIRM appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

MIRM vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 17 Nov 2026, Mirum Pharmaceuticals, Inc. returned +27.3% against +11.2% for the S&P 500, dividends included.

MIRM vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160180Jan 26Apr 26Jul 26Oct 26MIRMS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

MIRM analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Mirum Pharmaceuticals, Inc. (MIRM) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−200.1×

Cheaper than 99% of US stocks

Price / sales
9.1×

Cheaper than 14% of US stocks

Price / book
−571.8×

Cheaper than 99% of US stocks

EV / EBITDA
−55.0×

Cheaper than 95% of US stocks

Growth & margins
Revenue growth (YoY)
39.6%

Higher than 82% of US stocks

Earnings growth (YoY)
37.9%

Higher than 71% of US stocks

Gross margin
82.8%

Higher than 93% of US stocks

Operating margin
−21.6%

Higher than 21% of US stocks

Net margin
−134.8%

Higher than 4% of US stocks

Returns & dividend
Return on equity
−760.0%

Higher than 2% of US stocks

Return on assets
−10.0%

Higher than 26% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Mirum Pharmaceuticals, Inc. (MIRM) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Mirum Pharmaceuticals, Inc. has a market value of $6.1B and an enterprise value of $6.5B.

  • Revenue in the twelve months to 30 June 2026: $618.1M. The latest quarter grew 39.6% year on year.

  • Net income over the same four quarters: −$860.2M, a −139.2% net margin.

  • Diluted earnings per share, trailing twelve months: −$14.55.

  • Free cash flow in the twelve months to 30 June 2026: −$263.7M.

  • Shares outstanding: 64.8M.

  • Trailing P/E: −200.1×; forward P/E: 293.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Mirum Pharmaceuticals, Inc. employs 470 people — $1.3M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 17 Nov 2026

Data provided by Twelve Data

Peers

MIRM vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
MIRMMirum Pharmaceuticals, Inc.$6.1B56
CAICaris Life Sciences, Inc.$5.9B25
LGNDLigand Pharmaceuticals, Inc.$6.0B68
ARWRArrowhead Pharmaceuticals, Inc.$6.2B41
IBRXImmunityBio, Inc.$6.3B40
SRRKScholar Rock Holding Corp.$5.4B47
ORKAOruka Therapeutics, Inc.$6.6B37

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Mirum Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest MIRM news & analysis

AMG TimesSquare Small Cap Growth Fund Q3 2026 Portfolio Activity

Seeking Alpha · 15 Nov 2026neutral

AMG TimesSquare Small Cap Growth Fund said it outperformed the Russell 2000 Growth Index in Q3 2026. Holdings in Health Care offset part of the gain, though the excerpt does not identify specific companies.

Why it matters — The excerpt mentions Health Care sector positioning but gives no Mirum-specific information, so it offers little company-level context for MIRM watchers.

MIRM's Brelovitug Scores Second Phase III Win, Nears BLA Filing in HDV

Zacks Investment Research · 11 Nov 2026positive

Mirum Pharmaceuticals said brelovitug achieved a second Phase III win in chronic hepatitis D virus (HDV). The result brings the company closer to its planned 2027 BLA filing with the FDA.

Why it matters — The Phase III result is a milestone toward Mirum’s planned regulatory filing for brelovitug in chronic HDV.

FAQ

Frequently asked questions about MIRM stock

What is the MIRM stock price forecast for 2026-2027?

The 12 Wall Street analysts covering Mirum Pharmaceuticals, Inc. have a median 12-month price target of $155, with estimates ranging from $118 to $202. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is MIRM stock a buy right now?

Of the 12 analysts covering Mirum Pharmaceuticals, Inc., 12 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Mirum Pharmaceuticals, Inc. 56 out of 100 across roughly 4,600 US stocks as at 16 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MIRM?

As at 16 Nov 2026, Mirum Pharmaceuticals, Inc. ranks 56 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (92 of 100).

Will MIRM stock go up?

No one can know that. What the data says: the median 12-month target from 12 analysts implies +68.6% from the last close, and Ticker Nerd's factor model ranks Mirum Pharmaceuticals, Inc. 56 out of 100 as at 16 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the MIRM stock forecast for 2030?

No analyst covering Mirum Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MIRM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $118 to $202 over the next 12 months.

How has MIRM stock performed over the past year?

Mirum Pharmaceuticals, Inc. returned +27.3% over the 12 months to 17 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Mirum Pharmaceuticals, Inc. do?

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company focused on rare and orphan diseases, with particular strength in liver and bile-acid related disorders.

What is the latest news on MIRM?

The most recent item we track (Seeking Alpha, 15 Nov 2026): "AMG TimesSquare Small Cap Growth Fund Q3 2026 Portfolio Activity". AMG TimesSquare Small Cap Growth Fund said it outperformed the Russell 2000 Growth Index in Q3 2026. Holdings in Health Care offset part of the gain, though the excerpt does not identify specific companies.

Company

About Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company focused on rare and orphan diseases, with particular strength in liver and bile-acid related disorders. The company develops and commercializes approved medicines and investigational therapies designed for patients with serious conditions that have limited treatment options. Its commercial portfolio includes treatments for Alagille syndrome, progressive familial intrahepatic cholestasis, bile-acid synthesis disorders, and cerebrotendinous xanthomatosis, supported by a pipeline of additional rare-disease programs. Mirum operates as a specialty rare-disease company, combining drug development, regulatory expertise, and patient-support capabilities to serve children, adults, and families affected by complex genetic and metabolic conditions. Headquartered in Foster City, California, Mirum Pharmaceuticals plays a focused role in the global rare-disease market by bringing targeted therapies to highly specialized clinical settings.

CEO Mr. Christopher Peetz · 470 employees · United States · https://www.mirumpharma.com